Budget Impact Analysis of EGFR Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece

• DOI: 10.3390/diagnostics10060429
• Publication Date: 2020-06-24T14:54:59Z
• Authors: Mindy Cheng; Athanasios Akalestos; Sidney Scudder
• Keywords: Liquid biopsy

Within the European Union, Greece has highest incidence of lung cancer among people under 45 years age. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are indicated for treatment patients with EGFR mutation-positive metastatic non-small cell (mNSCLC). Tumor tissue biopsy is standard method mutation detection but invasive, resource-intensive, and risks complications. The objective this analysis was to estimate financial impact on Greek National Health System adopting plasma identify cost-optimal approach testing mNSCLC. We developed a budget model total costs three approaches: (1) test, (2) combined (tissue test), (3) reflex testing, compared current scenario only. One-way sensitivity analyses were conducted evaluate uncertainty variance different input parameters results. In first-line (1L) setting, base-case results showed that in identified more yielded cost savings (-€17 per correctly classified patient) relative alone. strategy second-line (2L) setting as it most -€42 patient This suggests access both important optimizing mNSCLC decisions Greece. Inclusion either or may be optimal test implementation.